IRIS Accounts Production v24.2.0.383 03005721 Board of Directors 1.7.23 30.6.24 30.6.24 false true false false true false Ordinary 0.0100 A Ordinary 0.0100 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh030057212023-06-30030057212024-06-30030057212023-07-012024-06-30030057212022-06-30030057212022-07-012023-06-30030057212023-06-3003005721ns15:EnglandWales2023-07-012024-06-3003005721ns14:PoundSterling2023-07-012024-06-3003005721ns10:Director12023-07-012024-06-3003005721ns10:PrivateLimitedCompanyLtd2023-07-012024-06-3003005721ns10:SmallEntities2023-07-012024-06-3003005721ns10:AuditExempt-NoAccountantsReport2023-07-012024-06-3003005721ns10:SmallCompaniesRegimeForDirectorsReport2023-07-012024-06-3003005721ns10:SmallCompaniesRegimeForAccounts2023-07-012024-06-3003005721ns10:FullAccounts2023-07-012024-06-3003005721ns10:OrdinaryShareClass12023-07-012024-06-3003005721ns10:OrdinaryShareClass22023-07-012024-06-3003005721ns10:Director22023-07-012024-06-3003005721ns10:Director32023-07-012024-06-3003005721ns10:CompanySecretary12023-07-012024-06-3003005721ns10:RegisteredOffice2023-07-012024-06-3003005721ns5:CurrentFinancialInstruments2024-06-3003005721ns5:CurrentFinancialInstruments2023-06-3003005721ns5:PlantMachinery2023-07-012024-06-3003005721ns5:PlantMachinery2023-06-3003005721ns5:PlantMachinery2024-06-3003005721ns5:PlantMachinery2023-06-3003005721ns10:OrdinaryShareClass12024-06-3003005721ns10:OrdinaryShareClass22024-06-3003005721ns5:RetainedEarningsAccumulatedLosses2023-07-012024-06-30
REGISTERED NUMBER: 03005721 (England and Wales)









UNAUDITED FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30TH JUNE 2024

FOR

ENDOCRINE PHARMACEUTICALS LIMITED

ENDOCRINE PHARMACEUTICALS LIMITED (REGISTERED NUMBER: 03005721)






CONTENTS OF THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30TH JUNE 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


ENDOCRINE PHARMACEUTICALS LIMITED

COMPANY INFORMATION
FOR THE YEAR ENDED 30TH JUNE 2024







DIRECTORS: L W Fairlie
Dr J E Hart
G F Douglas



SECRETARY: Mrs J F Hart



REGISTERED OFFICE: Wilderness End
Tadley Common Road
Tadley
Hampshire
RG26 3TA



REGISTERED NUMBER: 03005721 (England and Wales)



ACCOUNTANTS: Barker Wilkinson Limited
19-21 Middle Row
Stevenage
Hertfordshire
SG1 3AW



BANKERS: Bank of Ireland
1 Marsden Street
Manchester
M2 1HW

ENDOCRINE PHARMACEUTICALS LIMITED (REGISTERED NUMBER: 03005721)

BALANCE SHEET
30TH JUNE 2024

2024 2023
Notes £    £   
CURRENT ASSETS
Cash at bank 5,187 2,160

CREDITORS
Amounts falling due within one year 5 95,222 89,669
NET CURRENT LIABILITIES (90,035 ) (87,509 )
TOTAL ASSETS LESS CURRENT
LIABILITIES

(90,035

)

(87,509

)

CAPITAL AND RESERVES
Called up share capital 6 21,519 21,219
Share premium 7 2,648,230 2,642,530
Retained earnings 7 (2,759,784 ) (2,751,258 )
SHAREHOLDERS' FUNDS (90,035 ) (87,509 )

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 30th June 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 30th June 2024 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 24th August 2024 and were signed on its behalf by:





Dr J E Hart - Director


ENDOCRINE PHARMACEUTICALS LIMITED (REGISTERED NUMBER: 03005721)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30TH JUNE 2024

1. STATUTORY INFORMATION

Endocrine Pharmaceuticals Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The accounts have been prepared on the going concern basis which assumes that the company will continue in operational existence for the foreseeable future. As in past years, the company incurred a loss during the year, which was £8,525. The company is involved in research and development activities and while the company may require financial support from additional investments it is endeavouring to become cash positive via deals with industrial partners and by taking steps to market products direct to potential users. The directors are thus actively seeking further finance. Whilst the directors cannot be certain of future funding, based on progress to date they believe that it is appropriate for these statutory accounts to be prepared on a going concern basis.

Significant judgements and estimates
In the application of the company's accounting policies, management is required to make judgements, estimates and assumptions about the carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and underlying assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from those estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery - 20% on cost

Financial instruments
The directors consider all financial instruments to be basic financial instruments in accordance with Section 11 of FRS102. All basic financial instruments including trade and other debtors, cash and cash equivalents, and trade and other creditors, are initially recognised at transaction price and thereafter stated at amortised cost.

Taxation
Taxation for the year comprises current tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 3 (2023 - 3 ) .

ENDOCRINE PHARMACEUTICALS LIMITED (REGISTERED NUMBER: 03005721)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30TH JUNE 2024

4. TANGIBLE FIXED ASSETS
Plant and
machinery
£   
COST
At 1st July 2023
and 30th June 2024 886
DEPRECIATION
At 1st July 2023
and 30th June 2024 886
NET BOOK VALUE
At 30th June 2024 -
At 30th June 2023 -

5. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£    £   
Trade creditors 90 -
Taxation and social security 1,807 1,871
Other creditors 93,325 87,798
95,222 89,669

6. CALLED UP SHARE CAPITAL

Allotted, issued and fully paid:
Number: Class: Nominal 2024 2023
value: £    £   
11,708,751 Ordinary 0.001 11,709 11,409
9,811,315 A Ordinary 0.001 9,810 9,810
21,519 21,219

During February 2024 the company issued and allotted 300,000 ordinary £0.001 shares at a premium of £0.019 per share.

7. RESERVES
Retained Share
earnings premium Totals
£    £    £   

At 1st July 2023 (2,751,258 ) 2,642,530 (108,728 )
Deficit for the year (8,526 ) (8,526 )
Cash share issue - 5,700 5,700
At 30th June 2024 (2,759,784 ) 2,648,230 (111,554 )

ENDOCRINE PHARMACEUTICALS LIMITED (REGISTERED NUMBER: 03005721)

NOTES TO THE FINANCIAL STATEMENTS - continued
FOR THE YEAR ENDED 30TH JUNE 2024

8. RELATED PARTY DISCLOSURES

Officers of the company have an option to purchase shares at 2p, further to an EGM of 5 December 2013. The options are available to be exercised on gene validation. There are 3,340,000 share options in all.

A director's loan by John Hart of £11,625. is interest free. Repayment of this loan will not be sought in the financial year to 30th June 2025, unless funds permit, at the discretion of the Board. John Hart's subsidisation of the company over many years via provision of office and extensive archive facilities in Hampshire is acknowledged, as is the maintenance of a duplicate archive in Cheshire by shareholding scientist Dr Dave Copsey.

Aggregate Company Secretary fees amounting to £80,950 have been accrued to date but will only be paid at the discretion of the Board, funds permitting.